Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer

Gu,Fei; Zhang,Hao; Yao,Liangqing; Jiang,Shuheng; Lu,Huan; Xing,Xin; Zhang,Cancan; Jiang,Pengcheng; Zhang,Rong

doi:10.3892/ol.2019.10381

Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer

Authors:
- Fei Gu
- Hao Zhang
- Liangqing Yao
- Shuheng Jiang
- Huan Lu
- Xin Xing
- Cancan Zhang
- Pengcheng Jiang
- Rong Zhang
View Affiliations

Affiliations: The Third School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510500, P.R. China, Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, P.R. China, Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University, Shanghai 201499, P.R. China, Department of Obstetrics and Gynecology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China
Published online on: May 21, 2019 https://doi.org/10.3892/ol.2019.10381
Pages: 561-570
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial ovarian cancer (EOC) is a gynecological malignancy with high morbidity. Treating EOC remains a challenge, as the pathogenesis of this disease remains unclear and chemoresistance is a common occurrence. A number of previous studies have revealed that obesity is closely associated with cancer and leptin, as a link between cancer and obesity, has become a focus of research in recent years. In the present study, survival database analysis demonstrated that leptin expression was associated with poor prognoses in patients treated with platinum and paclitaxel/docetaxel. A cell activity assay demonstrated that leptin reduced the chemosensitivity of ovarian cancer cells to paclitaxel/docetaxel. Furthermore, flow cytometry results revealed that treatment with exogenous leptin reduced the proportion of ovarian cancer cells in G2/M phase, which was significantly elevated following paclitaxel/docetaxel chemotherapy. It was also verified that transcription factor CCAAT/Enhancer Binding Protein α can bind to the upstream promoter region of leptin and activate its transcription in ovarian cancer cells. Together, these results suggest that leptin serves an important role in chemoresistance and may serve as a novel therapeutic target for ovarian cancer in patients treated with platinum and paclitaxel chemotherapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, et al: Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 128:589–606. 2018. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
4	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
5	Batista ML Jr, Olivan M, Alcantara PS, Sandoval R, Peres SB, Neves RX, Silverio R, Maximiano LF, Otoch JP and Seelaender M: Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine. 61:532–539. 2013. View Article : Google Scholar : PubMed/NCBI
6	Andò S, Barone I, Giordano C, Bonofiglio D and Catalano S: The multifaceted mechanism of leptin signaling within tumor microenvironment in driving breast cancer growth and progression. Front Oncol. 4:3402014.PubMed/NCBI
7	Chang CC, Wu MJ, Yang JY, Camarillo IG and Chang CJ: Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression. Cancer Res. 75:2375–2386. 2015. View Article : Google Scholar : PubMed/NCBI
8	Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
9	Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B and Unluhizarci K: Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol. 24:117–121. 2008. View Article : Google Scholar : PubMed/NCBI
10	La Cava A and Matarese G: The weight of leptin in immunity. Nat Rev Immunol. 4:371–379. 2004. View Article : Google Scholar : PubMed/NCBI
11	Zhou W, Guo S and Gonzalez-Perez RR: Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer. 104:128–137. 2011. View Article : Google Scholar : PubMed/NCBI
12	Vernooy JHJ, Ubags ND, Brusselle GG, Tavernier J, Suratt BT, Joos GF, Wouters EF and Bracke KR: Leptin as regulator of pulmonary immune responses: Involvement in respiratory diseases. Pulm Pharmacol Ther. 26:464–472. 2013. View Article : Google Scholar : PubMed/NCBI
13	Geng Y, Wang J, Wang R, Wang K, Xu Y, Song G, Wu C and Yin Y: Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients. Biomed Pharmacother. 66:419–424. 2012. View Article : Google Scholar : PubMed/NCBI
14	Harbuzariu A, Rampoldi A, Daley-Brown DS, Candelaria P, Harmon TL, Lipsey CC, Beech DJ, Quarshie A, Ilies GO and Gonzalez-Perez RR: Leptin-Notch signaling axis is involved in pancreatic cancer progression. Oncotarget. 8:7740–7752. 2017. View Article : Google Scholar : PubMed/NCBI
15	Beales ILP, Garcia-Morales C, Ogunwobi OO and Mutungi G: Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol. 382:150–158. 2014. View Article : Google Scholar : PubMed/NCBI
16	Jin JH, Kim HJ, Kim CY, Kim YH, Ju W and Kim SC: Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer. Obstet Gynecol Sci. 59:279–285. 2016. View Article : Google Scholar : PubMed/NCBI
17	Housa D, Housová J, Vernerová Z and Haluzík M: Adipocytokines and cancer. Physiol Res. 55:233–244. 2006.PubMed/NCBI
18	Trisolini C, Albrizio M, Roscino MT, Pantaleo M, Rizzo A and Sciorsci RL: Leptin and queen ovary: New insights about ovulation. Res Vet Sci. 94:707–710. 2013. View Article : Google Scholar : PubMed/NCBI
19	Yu Y, Gaillard S, Phillip JM, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, et al: Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell. 28:82–96. 2015. View Article : Google Scholar : PubMed/NCBI
20	Khan IU, Khan RU, Asif H, Alamgeer, Khalid SH, Asghar S, Saleem M, Shah KU, Shah SU, Rizvi SAA and Shahzad Y: Co-delivery strategies to overcome multidrug resistance in ovarian cancer. Int J Pharm. 533:111–124. 2017. View Article : Google Scholar : PubMed/NCBI
21	Monk BJ, Herzog TJ and Tewari KS: Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients. Curr Pharm Des. 22:4717–4728. 2016. View Article : Google Scholar : PubMed/NCBI
22	Fletcher JI, Haber M, Henderson MJ and Norris MD: ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
23	Iyer AK, Singh A, Ganta S and Amiji MM: Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliver Rev. 65:1784–1802. 2013. View Article : Google Scholar
24	Jabr-Milane LS, van Vlerken LE, Yadav S and Amiji MM: Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 34:592–602. 2008. View Article : Google Scholar : PubMed/NCBI
25	Mahmood K, Zia KM, Zuber M, Salman M and Anjum MN: Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: A review. Int J Biol Macromol. 81:877–890. 2015. View Article : Google Scholar : PubMed/NCBI
26	Cuello MA, Kato S and Liberona F: The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: The underestimated driving force affecting prognosis. J Cell Mol Med. 22:1805–1815. 2018. View Article : Google Scholar : PubMed/NCBI
27	Otero M, Lago R, Lago F, Reino JJ and Gualillo O: Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: Synergistic effect of leptin with interleukin-1. Arthritis Res Ther. 7:R581–R591. 2005. View Article : Google Scholar : PubMed/NCBI
28	Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Päivärinta U, Moilanen T and Moilanen E: Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage-mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediators Inflamm. 2009:3458382009. View Article : Google Scholar : PubMed/NCBI
29	Liang SQ, Marti TM, Dorn P, Froment L, Hall SR, Berezowska S, Kocher G, Schmid RA and Peng RW: Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell Death Dis. 6:e18242015. View Article : Google Scholar : PubMed/NCBI
30	Mitra A, Mishra L and Li S: EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
31	Sánchez-Tilló E, Fanlo L, Siles L, Montes-Moreno S, Moros A, Chiva-Blanch G, Estruch R, Martinez A, Colomer D, Győrffy B, et al: The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ. 21:247–257. 2014. View Article : Google Scholar : PubMed/NCBI
32	Kim E, Lim S, Kim M, Yoo S and Kim Y: Phyllodulcin, a natural sweetener, regulates obesity-related metabolic changes and fat browning-related genes of subcutaneous white adipose tissue in high-fat diet-induced obese mice. Nutrients. 9(pii): E10492017. View Article : Google Scholar : PubMed/NCBI
33	Konopka B, Szafron LM, Kwiatkowska E, Podgorska A, Zolocinska A, Pienkowska-Grela B, Dansonka-Mieszkowska A, Balcerak A, Lukasik M, Stachurska A, et al: The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome. Oncotarget. 7:67412–67424. 2016. View Article : Google Scholar : PubMed/NCBI